coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI).
1)2) However, many studies have demonstrated wide inter-individual variability in the platelet response to clopidogrel.
3)4) High on-treatment platelet reactivity (HTPR) after receiving clopidogrel has been associated with an increased risk for adverse cardiovascular events in patients who underwent PCI.
5-8)
Prasugrel is a novel thienopyridine adenosine diphosphate (ADP)-receptor antagonist that has been shown to produce higher, more rapid and more consistent levels of platelet inhibition than standard and higher doses of clopidogrel due to the more efficient generation of active metabolite. [9] [10] [11] [12] The potent pharmacodynamic effect on platelet aggregation has resulted in improved ischemic outcomes but more bleeding compared with clopidogrel in patients with ACS who underwent PCI. 13) Increased bleeding tendency with standard dose prasugrel has led to increased questions about its effectiveness and safety at lower maintenance doses. A previous pharma-http://dx.doi.org/10.4070/kcj.2014.44.2.82 www.e-kcj.org codynamic study showed that 5 mg prasugrel was not inferior to 10 mg prasugrel in patients ≥75 years old or weighing <60 kg, in which the lower dose prasugrel was considered to reduce the rate of hemorrhagic complications.
14)15) However, pharmacodynamic effects of 5 mg prasugrel in heavier weight and younger patients who underwent percutaneous coronary stent implantation are unknown. Therefore, we compared the platelet inhibitory efficacy determined by the VerifyNow P2Y12 (Accumetrics, San Diego, CA, USA) point-ofcare assay between 5 mg prasugrel and 75 mg clopidogrel in nonlow body weight and non-elderly patients in the maintenance phase of dual antiplatelet therapy after percutaneous coronary stent implantation.
Subjects and Methods

Study population
This study was a prospective, open-label, randomized, controlled trial conducted to compare platelet inhibitory efficacy between 5 mg prasugrel and 75 mg clopidogrel in patients in the maintenance phase of dual antiplatelet therapy after percutaneous coronary stent implantation. Patients were considered eligible for this study if they were 18-74-years-of-age, ≥60 kg of body weight and were receiving dual antiplatelet therapy with aspirin and clopidogrel for at least 12 months. The main exclusion criteria were as follows: a history of ischemic or hemorrhagic stroke, a history of transient ischemic attack, body weight <60 kg, age ≥75 years, use of oral anticoagulants or NSAIDs, presence of active bleeding or bleeding diathesis, serum creatinine >2 mg/dL, platelet count ≤100000/mm 3 , serum liver enzymes greater than twice the upper limit of normal values, and clinical instability. Written consent was obtained from each subject, and this study was approved by the local institutional review board and was in accordance with the provisions of the Declaration of Helsinki.
Study design
The study design and patient disposition are illustrated in Fig. 1 . After assessing adherence to aspirin and clopidogrel therapy at the outpatient clinic to identify a steady-state level of pharmacodynamic effects, all subjects were randomly assigned to one of the following three groups: 75 mg clopidogrel, 5 mg prasugrel, or 10 mg prasugrel. Prasugrel (10 mg) was used as a reference for comparison. All subjects received the assigned drug without a loading dose and 100 mg aspirin once daily for 30 days.
Blood sampling and platelet function test
Samples for the platelet function test were collected at baseline and 30 days after randomization. Blood samples were taken through a short venous catheter inserted into a forearm vein after assessing compliance to the allocated antiplatelet drugs and were processed for platelet function test within 60 minutes after the draw. Platelet function was assessed using the VerifyNow P2Y12 assay (Accumetrics), which is a turbidimetry-based optical detection device that measures responsiveness to clopidogrel, prasugrel, and other platelet ADP P2Y12 receptor antagonists. Results are expressed in P2Y12 reaction units (PRU), determined by the measurement of platelet ag- gregation in response to ADP, BASE, and percent inhibition.
16) The percent platelet inhibition is calculated as: { (BASE-PRU)/BASE }× 100.
Study endpoints
The primary endpoint was PRU values between the 75 mg clopidogrel and 5 mg prasugrel groups 30 days after randomization. The secondary endpoints included the percent change in the PRU calculated as the relative difference in PRUs at baseline and at 30 days: { (PRU at baseline-PRU at 30 days)/(PRU at baseline) }× 100, the rates of HTPR defined as >235 PRU, and percent platelet inhibition.
17)18)
Safety regarding bleeding events was also assessed based on the incidence of adverse events, signs and symptoms, laboratory data, and vital signs. Bleeding was classified as major, minor, or insignificant according to the Thrombolysis in Myocardial Infarction (TIMI) criteria.
13)
Sample size calculation and statistical analysis
We previously performed a pilot study to compare PRU values between 5 mg prasugrel and 75 mg clopidogrel in 20 patients who were <75 years and weighed ≥60 kg. PRU values were 171.6±52.1 and 208±87.6 in the 5 mg prasugrel and 75 mg clopidogrel groups, respectively. We hypothesized that 5 mg prasugrel would result in a reduction of 37 PRU compared with 75 mg clopidogrel with a difference of the standard deviation between the two groups to be 35. Therefore, considering a dropout rate of approximately of 10%, 20 patients in each group were needed to provide at least a 90% power to detect significant differences between treatment groups with a two-tailed alpha value <0.05. Continuous variables are presented as means±standard deviations. Categorical variables are presented as frequencies and group percentages. Analysis of variance or the Kruskal-Wallis test was used for comparing baseline continuous variables among the three groups. Student's t-test or the MannWhitney U-test was used for comparing continuous variable between two groups 30 days after randomization. Fisher's exact test was used to compare categorical variables. All statistical tests were two-tailed and a p<0.05 was considered significant. All calculations were performed using Statistical Package for the Social Sciences 14 (SPSS Inc., Chicago, IL, USA).
Results
Patients
From June 2012 to August 2012, 75 patients were screened and 68 patients were enrolled in the study. Of these, 63 patients (23 patients on 75 mg clopidogrel, 20 patients each on 5 mg and 10 mg prasugrel) completed the study and were included in the pharmacodynamic analysis to assess the study endpoints. The patient's baseline clinical characteristics and medication 30 days after randomization are shown in Table 1 and 2, respectively. No significant differences were observed in the baseline characteristics among the three groups.
Inhibition of platelet aggregation
Baseline PRU values and percent platelet inhibition were not dif- (Fig. 2) . Similarly, the 5 mg prasugrel group demonstrated a higher percent platelet inhibition compared to that of the 75 mg clopidogrel group at 30 days (Table 3 ). In addition, the percent change in the PURs was significantly higher in the 5 mg prasugrel than that in the 75 mg clopidogrel group (18.7±20.8 vs. -1.17±18.9, p=0.002) and higher in the 10 mg prasugrel (61.7±20.5) than that in the 5 mg prasugrel group (p<0.001). The proportion of baseline HTPR was similar in each group (p=0.392). At 30 days after switching to the study drugs, the rate of HTPR was significantly lower in the 5 mg prasugrel than that in the 75 mg clopidogrel group (15.0% vs. 56.5%, p=0.010) (Fig. 3) . When we used a more sensitive PRU cut-off value (>208) predicting ischemic events, there were still differences in the rate of HTPR (30.0% vs. 60.9%) although statistical significance was borderline (p=0.067).
Safety
Thrombolysis in Myocardial Infarction major bleeding or life threatening bleeding events did not occur during the study period in any of the treatment groups. Three insignificant bleeding events occurred, including two episodes of recurrent bruising and one episode of epistaxis in the 10 mg prasugrel group. An episode of self-limiting bruising was also observed in the 75 mg clopidogrel and 5 mg prasugrel groups. One patient experience headache on 5 mg prasugrel and discontinued the drug. The other adverse events were mild or not considered to be related to the study drug. 
Discussion
The present randomized study is the first to assess the platelet inhibitory efficacy of a lower maintenance dose (5 mg daily) of prasugrel compared with a standard dose of clopidogrel and 10 mg prasugrel in patients <75 years and ≥60 kg who underwent PCI. The results of our trial demonstrated that the 5 mg prasugrel dose provided stronger platelet inhibition than that of 75 mg clopidogrel in this cohort of patients in the maintenance phase with aspirin and clopidogrel after PCI. Furthermore, the rate of HTPR, defined as a PRU value >235, was significantly lower in patients treated with 5 mg prasugrel compared with those treated with 75 mg clopidogrel; however, no significant TIMI bleeding was observed in patients who received 5 mg prasugrel or 75 mg clopidogrel.
Prasugrel has a more potent, rapid, and consistent antiplatelet effect than that of clopidogrel, although both drugs have similar binding affinities to the P2Y12 receptor, it is associated with more efficient generation of active metabolites. [9] [10] [11] [12] The stronger antiplatelet effect of 10 mg prasugrel provides the clinical benefit of reducing ischemic events but more bleeding events occur compared with that of 75 mg clopidogrel in ACS patients undergoing PCI. 13) In contrast, 10 mg prasugrel does not significantly reduce the frequency of major ischemic events compared with 75 mg clopidogrel in patients with ACS without revascularization. 19) In addition, the high platelet reactivity of clopidogrel was inversely related to bleeding but was not related to mortality. 20) With growing concern about bleeding risk, the US Food and Drug Administration and the European Medicine Agency added warnings that prasugrel can cause serious bleeding and 10 mg prasugrel is generally not recommended in patients ≥75 years and weighing <60 kg. For elderly or lower body weight patients, 5 mg prasugrel daily is recommended as a maintenance dose to decrease bleeding complications. 22) The incidence and clinical significance of bleeding have been underestimated in patients treated with PCI. Most randomized trials did not include patients with high risk of bleeding, such as renal failure on dialysis and bleeding diathesis, so they did not reflect the bleeding rate in real clinical practice. Furthermore, a recent study showed that bleeding events, even TIMI minor bleeding, are significantly associated with higher short and long-term mortality in patients with ACS. [23] [24] [25] Additionally, Wiviott et al. 13)26) reported significantly greater TIMI major and minor bleeding with 10 mg prasugrel than that with clopidogrel (3.9% vs. 3.0%, hazard ratio, 1.26; 95% confidence interval, 1.02-1.57, p= 0.033) in the TRITON-TIMI population even <75 years old and weighing ≥60 kg, although the net clinical benefit favors 10 mg prasugrel compared with clopidogrel in those groups. There has been growing questions about 5 mg prasugrel as a maintenance dose to reduce bleeding complications and whether it provides an adequate antiplatelet inhibitory effect in patients at high risk for bleeding. Up to now, the platelet inhibitory effect or clinical efficacy of 5 mg prasugrel in non-low body weight and non-elderly patients after PCI has not been well established. The recent platelet function substudy of the TRIOLOGY ACS trial showed that the antiplatelet efficacy of 5 mg prasugrel was significantly greater than that of 75 mg clopidogrel using the VerifyNow P2Y12 assay in non-elderly patients (<75 that the lower maintenance dose of 5 mg prasugrel had a more potent platelet inhibitory effect with a lower mean PRU and lower HTPR rate compared with 75 mg clopidogrel in patients <75 years and >60 kg who underwent PCI. Interestingly, the mean PRU value of 5 mg prasugrel was between those of 10 mg prasugrel and 75 mg clopidogrel, which may indicate that 5 mg prasugrel provides a more potent platelet inhibitory effect compared with that of 75 mg clopidogrel and has a lower risk for bleeding compared to that of 10 mg prasugrel. Although no TIMI major or minor bleeding events were observed during the study, 10 mg prasugrel tended to cause more bleeding events with high platelet inhibition compared with that of lower dose prasugrel and 75 mg clopidogrel. Bleeding complications were similar in 5 mg prasugrel and 75 mg clopidogrel groups, although 5 mg prasugrel manifested a greater antiplatelet effect.
These results provide pharmacodynamic evidence that 5 mg prasugrel can be alternative maintenance therapy to 75 mg clopidogrel or 10 mg prasugrel for reducing hemorrhagic complications with adequate platelet inhibition in patients <75 years and ≥60 kg who are at high risk for bleeding, such patients with renal failure, previous bleeding events, or hematologic disease, as well as older or lower body weight patients.
There are several limitations to this study. First, we measured platelet reactivity by only one method, which was the VerifyNow P2Y12 point-of-care assay. According to the POPULAR study, which performed a head-to-head comparison between the various methods for assessing platelet reactivity, VerifyNow P2Y12 point-of-care assay is one of the available platelet function tests for detecting high platelet reactivity or predicting clinical outcomes.
30) Second, the follow-up platelet function test was performed only 30 days after taking the study drugs. Therefore, we could not show the early platelet inhibitory effect by 5 mg prasugrel compared with 75 mg clopidogrel. Third, this study was conducted only in patients on the maintenance phase at least 12 months after PCI. Thus, these data cannot be generalized to all patients on the maintenance phase of antiplatelet therapy. Fourth, our study population consisted of patients with ACSs, as well as patients with stable angina. However, all patients had been in the stable state for at least 1 year since the index procedure was performed. Therefore, we do not think that difference in the clinical presentation at the index PCI affected the final results.
Last, our trial was designed to compare platelet inhibitory efficacy between study drugs and was not powered to assess clinical events or safety. Hence, the results of bleeding complications or clinical adverse events should be interpreted with caution for applying to real clinical practice.
In conclusion, the results of this study demonstrate that 5 mg prasugrel is associated with greater platelet inhibition with lower rates of HTPR compared with a standard dose of clopidogrel in patients <75 years old and weighing ≥60 kg after undergoing PCI. These results show that 5 mg prasugrel may be a better alternative maintenance antiplatelet therapy in non-low body weight and nonelderly patients who need more potent platelet inhibitory effect. The clinical implication of our data should be investigated in a future clinical trial.
